U.S. Markets open in 3 hrs 5 mins

Should Marker Therapeutics (NASDAQ:MRKR) Be Disappointed With Their 89% Profit?

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. To wit, the Marker Therapeutics, Inc. (NASDAQ:MRKR) share price is 89% higher than it was a year ago, much better than the market return of around 4.1% (not including dividends) in the same period. If it can keep that out-performance up over the long term, investors will do very well! Zooming out, the stock is actually down 25% in the last three years.

View our latest analysis for Marker Therapeutics

Marker Therapeutics recorded just US$205,994 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. As a result, we think it's unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. It seems likely some shareholders believe that Marker Therapeutics has the funding to invent a new product before too long.

As a general rule, if a company doesn't have much revenue, and it loses money, then it is a high risk investment. There is almost always a chance they will need to raise more capital, and their progress - and share price - will dictate how dilutive that is to current holders. While some such companies go on to make revenue, profits, and generate value, others get hyped up by hopeful naifs before eventually going bankrupt. Of course, if you time it right, high risk investments like this can really pay off, as Marker Therapeutics investors might know.

Marker Therapeutics has plenty of cash in the bank, with net cash sitting at US$59m, when it last reported (December 2018). That allows management to focus on growing the business, and not worry too much about raising capital. And with the share price up 89% in the last year, the market is focussed on that blue sky potential. You can click on the image below to see (in greater detail) how Marker Therapeutics's cash levels have changed over time.

NasdaqCM:MRKR Historical Debt, May 10th 2019

It can be extremely risky to invest in a company that doesn't even have revenue. There's no way to know its value easily. One thing you can do is check if company insiders are buying shares. It's usually a positive if they have, as it may indicate they see value in the stock. Luckily we are in a position to provide you with this free chart of insider buying (and selling).

A Different Perspective

It's good to see that Marker Therapeutics has rewarded shareholders with a total shareholder return of 89% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 29% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.